Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 3
2012 8
2013 6
2014 7
2015 6
2016 6
2017 6
2018 8
2019 8
2020 12
2021 12
2022 13
2023 19
2024 16
2025 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

116 results

Results by year

Filters applied: . Clear all
Page 1
Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study.
Leighl NB, Akamatsu H, Lim SM, Cheng Y, Minchom AR, Marmarelis ME, Sanborn RE, Chih-Hsin Yang J, Liu B, John T, Massutí B, Spira AI, Lee SH, Wang J, Li J, Liu C, Novello S, Kondo M, Tamiya M, Korbenfeld E, Moskovitz M, Han JY, Alexander M, Joshi R, Felip E, Voon PJ, Danchaivijitr P, Hsu PC, Silva Melo Cruz FJ, Wehler T, Greillier L, Teixeira E, Nguyen D, Sabari JK, Qin A, Kowalski D, Şendur MAN, Xie J, Ghosh D, Alhadab A, Haddish-Berhane N, Clemens PL, Lorenzini P, Verheijen RB, Gamil M, Bauml JM, Baig M, Passaro A; PALOMA-3 Investigators. Leighl NB, et al. J Clin Oncol. 2024 Oct 20;42(30):3593-3605. doi: 10.1200/JCO.24.01001. Epub 2024 Jun 10. J Clin Oncol. 2024. PMID: 38857463 Free PMC article. Clinical Trial.
BRD4 inhibition sensitizes diffuse large B-cell lymphoma cells to ferroptosis.
Schmitt A, Grimm M, Kreienkamp N, Junge H, Labisch J, Schuhknecht L, Schönfeld C, Görsch E, Tibello A, Menck K, Bleckmann A, Lengerke C, Rosenbauer F, Grau M, Zampieri M, Schulze-Osthoff K, Klener P, Dolnikova A, Lenz G, Hailfinger S. Schmitt A, et al. Among authors: bleckmann a. Blood. 2023 Sep 28;142(13):1143-1155. doi: 10.1182/blood.2022019274. Blood. 2023. PMID: 37294920 Free article.
Reciprocal interactions between innate immune cells and astrocytes facilitate neuroinflammation and brain metastasis via lipocalin-2.
Adler O, Zait Y, Cohen N, Blazquez R, Doron H, Monteran L, Scharff Y, Shami T, Mundhe D, Glehr G, Kanner AA, Horn S, Yahalom V, Haferkamp S, Hutchinson JA, Bleckmann A, Nahary L, Benhar I, Yust Katz S, Pukrop T, Erez N. Adler O, et al. Among authors: bleckmann a. Nat Cancer. 2023 Mar;4(3):401-418. doi: 10.1038/s43018-023-00519-w. Epub 2023 Feb 16. Nat Cancer. 2023. PMID: 36797502
Molecular differences of angiogenic versus vessel co-opting colorectal cancer liver metastases at single-cell resolution.
Fleischer JR, Schmitt AM, Haas G, Xu X, Zeisberg EM, Bohnenberger H, Küffer S, Teuwen LA, Karras PJ, Beißbarth T, Bleckmann A, Planque M, Fendt SM, Vermeulen P, Ghadimi M, Kalucka J, De Oliveira T, Conradi LC. Fleischer JR, et al. Among authors: bleckmann a. Mol Cancer. 2023 Jan 24;22(1):17. doi: 10.1186/s12943-023-01713-1. Mol Cancer. 2023. PMID: 36691028 Free PMC article.
Liquid Biopsies in Lung Cancer.
Kemper M, Krekeler C, Menck K, Lenz G, Evers G, Schulze AB, Bleckmann A. Kemper M, et al. Among authors: bleckmann a. Cancers (Basel). 2023 Feb 23;15(5):1430. doi: 10.3390/cancers15051430. Cancers (Basel). 2023. PMID: 36900221 Free PMC article. Review.
Microvesicles in Cancer: Small Size, Large Potential.
Menck K, Sivaloganathan S, Bleckmann A, Binder C. Menck K, et al. Among authors: bleckmann a. Int J Mol Sci. 2020 Jul 28;21(15):5373. doi: 10.3390/ijms21155373. Int J Mol Sci. 2020. PMID: 32731639 Free PMC article. Review.
Outcome of First-Line Treatment With Pembrolizumab According to KRAS/TP53 Mutational Status for Nonsquamous Programmed Death-Ligand 1-High (≥50%) NSCLC in the German National Network Genomic Medicine Lung Cancer.
Bischoff P, Reck M, Overbeck T, Christopoulos P, Rittmeyer A, Lüders H, Kollmeier J, Kulhavy J, Kemper M, Reinmuth N, Röper J, Janning M, Sommer L, Aguinarte L, Koch M, Wiesweg M, Wesseler C, Waller CF, Kauffmann-Guerrero D, Stenzinger A, Stephan-Falkenau S, Trautmann M, Lassmann S, Tiemann M, Klauschen F, Sebastian M, Griesinger F, Wolf J, Loges S, Frost N; National Network Genomic Medicine Lung Cancer (nNGM) Collaborator Group. Bischoff P, et al. J Thorac Oncol. 2024 May;19(5):803-817. doi: 10.1016/j.jtho.2023.12.015. Epub 2023 Dec 13. J Thorac Oncol. 2024. PMID: 38096950 Free article.
116 results